QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Immunovant (IMVT) Stock Forecast & Price Target

$36.01
+2.47 (+7.36%)
(As of 11/28/2023 ET)
Compare
Today's Range
$32.35
▼
$36.81
50-Day Range
$20.28
▼
$39.96
52-Week Range
$12.40
▼
$44.19
Volume
3.42 million shs
Average Volume
1.37 million shs
Market Capitalization
$5.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.54
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Immunovant Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$42.54
18.13% Upside
High Forecast$57.00
Average Forecast$42.54
Low Forecast$21.00
TypeCurrent Forecast
11/28/22 to 11/28/23		1 Month Ago
10/29/22 to 10/29/23		3 Months Ago
8/30/22 to 8/30/23		1 Year Ago
11/28/21 to 11/28/22
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
11 Buy rating(s)
4 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$42.54$41.15$27.92$14.43
Predicted Upside18.13% Upside27.72% Upside44.39% Upside38.88% Upside
Get Immunovant Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.


IMVT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IMVT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Immunovant Stock vs. The Competition

TypeImmunovantMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside18.13% Upside980.11% Upside2,838.32% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$30.00 ➝ $48.00+36.95%
10/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$28.00 ➝ $57.00+64.74%
10/24/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$29.00 ➝ $47.00+39.05%
10/16/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$30.00 ➝ $45.00+19.24%
10/13/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$18.00 ➝ $55.00+55.90%
9/27/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$32.00 ➝ $48.00+14.75%
9/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$33.00 ➝ $50.00+25.13%
9/27/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$33.00 ➝ $48.00+20.12%
9/26/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeMarket Perform ➝ Outperform$40.00+7.79%
7/18/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy$28.00 ➝ $34.00+47.00%
7/10/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Barcus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
5/23/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$26.00 ➝ $28.00+17.55%
2/6/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOutperform$14.00 ➝ $21.00+18.31%
(Data available from 11/28/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












IMVT Price Target - Frequently Asked Questions

What is Immunovant's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Immunovant stock is Buy based on the current 13 buy ratings for IMVT. The average twelve-month price prediction for Immunovant is $42.54 with a high price target of $57.00 and a low price target of $21.00. Learn more on IMVT's analyst rating history.

Do Wall Street analysts like Immunovant more than its competitors?

Analysts like Immunovant more than other Medical companies. The consensus rating for Immunovant is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how IMVT compares to other companies.

Is Immunovant being upgraded by Wall Street analysts?

Over the previous 90 days, Immunovant's stock had 2 upgrades by analysts.

Does Immunovant's stock price have much upside?

According to analysts, Immunovant's stock has a predicted upside of 33.65% based on their 12-month stock forecasts.

What analysts cover Immunovant?

Immunovant has been rated by Cantor Fitzgerald, Citigroup, Guggenheim, HC Wainwright, Piper Sandler, Raymond James, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:IMVT) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -